Clovis Oncology announced today updated findings from the Phase 1 and early Phase 2 portions of its ongoing Phase 1/2 clinical study of CO-1686, the Company’s novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation ...
News Source
News Source
No comments:
Post a Comment